Table 3.
Effect of chronic administration of Vigiis 101-LAB capsule II or placebo on blood lipid, blood glucose balance, liver, kidney function, and electrolyte balance profiles of subjects (clinical trial II).
| Treatment group |
Placebo group |
||||||
|---|---|---|---|---|---|---|---|
| Initial (0 wk) | Administration (4 wk) | Follow-up (6 wk) | Initial (0 wk) | Administration (4 wk) | Follow-up (6 wk) | ||
| TC | (mg/dL) | 171.1 ± 24.6 | 172.9 ± 24.7 | 170.3 ± 22.8 | 167.6 ± 21.0 | 172.5 ± 19.5 | 173.3 ± 23.1 |
| TG | 72.6 ± 29.2 | 76.9 ± 30.5 | 75.8 ± 33.5 | 76.4 ± 39.3 | 72.9 ± 25.6 | 85.3 ± 38.6 | |
| LDL-C | 96.2 ± 21.6 | 100.8 ± 25.0 | 98.4 ± 23.6 | 89.8 ± 20.4 | 94.0 ± 18.0 | 93.4 ± 21.4 | |
| HDL-C | 55.8 ± 7.7 | 54.6 ± 8.8 | 52.7 ± 8.8 | 59.1 ± 12.2 | 60.5 ± 11.5 | 58.8 ± 12.0 | |
| FBG | 88.9 ± 5.6 | 87.9 ± 5.2 | 88.1 ± 4.9 | 87.6 ± 4.6 | 86.2 ± 4.0 | 84.0 ± 5.7 | |
| HbA1c | (%) | 5.2 ± 0.2 | 5.2 ± 0.2 | 5.2 ± 0.2 | 5.2 ± 0.2 | 5.1 ± 0.2 | 5.2 ± 0.2 |
| AST | (IU/L) | 19.2 ± 2.6 | 17.8 ± 2.6 | 18.4 ± 2.5 | 20.5 ± 3.5 | 19.9 ± 3.6 | 20.9 ± 4.1 |
| ALT | 17.0 ± 3.9 | 16.3 ± 3.8 | 17.4 ± 4.0 | 19.1 ± 7.6 | 18.0 ± 7.2 | 20.0 ± 7.8 | |
| γ-GT | 11.7 ± 3.0 | 12.2 ± 3.0 | 11.9 ± 2.7 | 16.8 ± 10.4 | 18.8 ± 12.4 | 19.0 ± 12.5 | |
| Albumin | (g/dL) | 4.4 ± 0.2 | 4.6 ± 0.2 | 4.5 ± 0.2 | 4.3 ± 0.2 | 4.5 ± 0.2 | 4.5 ± 0.21 |
| Total-protein | 7.1 ± 0.3 | 7.2 ± 0.3 | 7.2 ± 0.3 | 7.0 ± 0.3 | 7.1 ± 0.3 | 7.2 ± 0.23 | |
| BUN | (mg/dL) | 10.8 ± 2.4 | 9.6 ± 2.3 | 10.6 ± 1.8 | 10.8 ± 2.3 | 10.4 ± 2.3 | 11.4 ± 2.6 |
| UA | 5.1 ± 0.9 | 5.0 ± 0.8 | 5.2 ± 0.8 | 4.9 ± 0.7 | 4.9 ± 0.8 | 5.1 ± 0.7 | |
| Creatinine | 0.8 ± 0.1 | 0.8 ± 0.1 | 0.8 ± 0.1 | 0.8 ± 0.2 | 0.8 ± 0.2 | 0.8 ± 0.2 | |
| Ca | (mg/dL) | 9.4 ± 0.2 | 9.7 ± 0.3 | 9.6 ± 0.3 | 9.4 ± 0.2 | 9.5 ± 0.2 | 9.6 ± 0.2 |
| P | 4.1 ± 0.4 | 4.2 ± 0.4 | 4.3 ± 0.5 | 4.2 ± 0.4 | 4.2 ± 0.4 | 4.1 ± 0.4 | |
| Mg | 2.1 ± 0.1 | 2.1 ± 0.1 | 2.1 ± 0.1 | 2.1 ± 0.1 | 2.1 ± 0.1 | 2.1 ± 0.1 | |
| N | (mmol/L) | 138.7 ± 1.6 | 139.6 ± 1.3 | 138.6 ± 0.9 | 138.4 ± 1.3 | 139.0 ± 1.2 | 138.4 ± 1.3 |
| K | 4.1 ± 0.2 | 4.1 ± 0.1 | 4.1 ± 0.2 | 4.1 ± 0.2 | 4.1 ± 0.2 | 4.1 ± 0.2 | |
| Cl | 105.2 ± 1.4 | 103.9 ± 1.3 | 104.0 ± 1.3 | 105.6 ± 1.8 | 104.3 ± 1.4 | 103.8 ± 1.5 | |
| Fe | (μg/dL) | 86.2 ± 25.6 | 88.7 ± 31.9 | 70.9 ± 27.0 | 73.3 ± 21.6 | 81.6 ± 22.1 | 86.2 ± 32.1 |
| CPK | (IU/L) | 102.3 ± 39.4 | 85.1 ± 27.0 | 90.7 ± 29.6 | 93.4 ± 32.5 | 91.0 ± 38.3 | 86.1 ± 38.4 |
TC: total cholesterol; TG: triglyceride; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; FBG: fasting blood glucose; HbA1c: glycated hemoglobin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GTP, γ-glutamyl transpeptidase; BUN, blood urea nitrogen. UA: uric acid. CPK: creatinine phosphokinase. Student's t-test, no significant difference between placebo and treatment groups at week 0. Values are mean ± SD (treatment group: n = 27; placebo group: n = 25).